Literature DB >> 26047823

Enabling minimal invasive parathyroidectomy for patients with primary hyperparathyroidism using Tc-99m-sestamibi SPECT-CT, ultrasound and first results of (18)F-fluorocholine PET-CT.

Wouter P Kluijfhout1, Wessel M C M Vorselaars2, Menno R Vriens3, Inne H M Borel Rinkes4, Gerlof D Valk5, Bart de Keizer6.   

Abstract

OBJECTIVE: Assessment of the diagnostic value of ultrasound (US), single photon-emission computed tomography-computed tomography (SPECT-CT) and (18)F-fluorocholine (FCH) PET-CT for preoperative localization of hyper-functioning parathyroid(s) in order to create a more efficient diagnostic pathway and enable minimal invasive parathyroidectomy (MIP) in patients with biochemical proven non-familial primary hyperparathyroidism (pHPT).
METHODS: A single-institution retrospective study of 63 consecutive patients with a biochemical diagnosis of non-familial pHPT who received a Tc-99m-sestamibi SPECT-CT and neck ultrasound. Surgical findings were used in calculating the sensitivity and the positive predictive value (PPV) of both imaging modalities. Furthermore we present 5 cases who received additional FCH PET-CT.
RESULTS: A total of 42 (66.7%) patients underwent MIP. The PPV and sensitivity of SPECT-CT, 93.0% and 80.3%, were significantly higher than those of US with 78.3% and 63.2%, respectively. Adding US to SPECT-CT for initial pre-operative localization did not significantly increase sensitivity but did significantly decrease PPV. Performance of US was significantly better when performed after SPECT-CT. (18)F-fluorocholine PET-CT localized the hyper-functioning parathyroid gland in 4/5 cases with discordant conventional imaging, enabling MIP.
CONCLUSION: SPECT-CT is the imaging modality of choice for initial pre-operative localization of hyper-functioning parathyroid gland(s) in patients with biochemical pHPT. Ultrasound should be performed after SPECT-CT for confirmation of positive SPECT-CT findings and for pre-operative marking allowing MIP. In cases with negative or discordant imaging additional FCH PET-CT should be considered since this might enable the surgeon to perform MIP.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  (18)F-fluorocholine; PET–CT; Primary hyperparathyroidism; SPECT–CT; Tc99m-sestamibi; Ultrasound

Mesh:

Substances:

Year:  2015        PMID: 26047823     DOI: 10.1016/j.ejrad.2015.05.024

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  19 in total

1.  Diagnostic performance of choline PET for detection of hyperfunctioning parathyroid glands in hyperparathyroidism: a systematic review and meta-analysis.

Authors:  Giorgio Treglia; Arnoldo Piccardo; Alessio Imperiale; Klaus Strobel; Philipp A Kaufmann; John O Prior; Luca Giovanella
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-09       Impact factor: 9.236

2.  Challenging pre-surgical localization of hyperfunctioning parathyroid glands in primary hyperparathyroidism: the added value of 18F-Fluorocholine PET/CT.

Authors:  Serena Grimaldi; Jacques Young; Peter Kamenicky; Dana Hartl; Marie Terroir; Sophie Leboulleux; Amandine Berdelou; Julien Hadoux; Segolene Hescot; Hervé Remy; Eric Baudin; Martin Schlumberger; Désirée Deandreis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-22       Impact factor: 9.236

3.  18F-Fluorocholine PET/CT and Parathyroid 4D Computed Tomography for Primary Hyperparathyroidism: The Challenge of Reoperative Patients.

Authors:  Coralie Amadou; Géraldine Bera; Malek Ezziane; Linda Chami; Thierry Delbot; Agnès Rouxel; Monique Leban; Genevieve Herve; Fabrice Menegaux; Laurence Leenhardt; Aurélie Kas; Christophe Trésallet; Cécile Ghander; Charlotte Lussey-Lepoutre
Journal:  World J Surg       Date:  2019-05       Impact factor: 3.352

4.  Diagnostic accuracy of 3T magnetic resonance imaging in the preoperative localisation of parathyroid adenomas: comparison with ultrasound and 99mTc-sestamibi scans.

Authors:  Renato Argirò; Daniele Diacinti; Beatrice Sacconi; Angelo Iannarelli; Davide Diacinti; Cristiana Cipriani; Daniela Pisani; Elisabetta Romagnoli; Marco Biffoni; Cira Di Gioia; Jessica Pepe; Mario Bezzi; Claudio Letizia; Salvatore Minisola; Carlo Catalano
Journal:  Eur Radiol       Date:  2018-05-07       Impact factor: 5.315

5.  18Fluorocholine PET/CT scanning with arterial phase-enhanced CT is useful for persistent/recurrent primary hyperparathyroidism: first UK case series results.

Authors:  I Christakis; S Khan; G P Sadler; F V Gleeson; K M Bradley; R Mihai
Journal:  Ann R Coll Surg Engl       Date:  2019-07-15       Impact factor: 1.891

6.  Retrospective real-life study on preoperative imaging for minimally invasive parathyroidectomy in primary hyperparathyroidism.

Authors:  Jacqueline Bijnens; Annick Van den Bruel; Vincent Vander Poorten; Ingeborg Goethals; Steven Van Schandevyl; Catherine Dick; Frank De Geeter
Journal:  Sci Rep       Date:  2022-10-19       Impact factor: 4.996

7.  Comparison of hyperparathyroidism types and utility of dual radiopharmaceutical acquisition with Tc99m sestamibi and 123I for localization of rapid washout parathyroid adenomas.

Authors:  Y S Kushchayeva; S H Tella; S V Kushchayev; D Van Nostrand; K Kulkarni
Journal:  Osteoporos Int       Date:  2019-01-31       Impact factor: 4.507

8.  Benefit of 18F-fluorocholine PET imaging in parathyroid surgery.

Authors:  G F Huber; M Hüllner; C Schmid; A Brunner; B Sah; D Vetter; P A Kaufmann; G K von Schulthess
Journal:  Eur Radiol       Date:  2018-01-25       Impact factor: 5.315

9.  Bilateral giant parathyroid adenoma in the absence of multiple endocrine neoplasia type 1.

Authors:  P Liu; N Vakharia; A Zacharia; M Rogers; F Tanweer
Journal:  Ann R Coll Surg Engl       Date:  2020-04-01       Impact factor: 1.891

10.  The EANM practice guidelines for parathyroid imaging.

Authors:  Petra Petranović Ovčariček; Luca Giovanella; Ignasi Carrió Gasset; Elif Hindié; Martin W Huellner; Markus Luster; Arnoldo Piccardo; Theresia Weber; Jean-Noël Talbot; Frederik Anton Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-04-10       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.